Unresectable Cholangiocarcinoma
Oncology·MeSH: Cholangiocarcinoma
Prevalence
2.5 / 100K
Incidence
1.3 / 100K/yr
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| pemigatinib | Incyte Corp. (INCY) |
Frequently asked questions
How many drugs are in development for Unresectable Cholangiocarcinoma?
BioSniper tracks 1 drug in development for Unresectable Cholangiocarcinoma across 1 company.
How many clinical trials target Unresectable Cholangiocarcinoma?
There are 2 clinical trials targeting Unresectable Cholangiocarcinoma tracked by BioSniper.
What is the prevalence of Unresectable Cholangiocarcinoma?
The estimated prevalence of Unresectable Cholangiocarcinoma is approximately 2.5 per 100,000 population.
Deep-dive into Unresectable Cholangiocarcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis